Monte Rosa Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Monte Rosa Therapeutics, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$123.67M	$75.62M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$54.21M	-$81.11M	-$72.88M
Operating income as a percentage of revenue.	-43.8%	-107.3%	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$38.63M	-$72.70M	-$73.96M
Net income divided by the number of shares outstanding — profit attributable to each share.	–	–	$-2.96

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$129.88M	$224.25M	$346.07M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$448.66M	$438.73M	$366.33M
Everything the company owes — debt, unpaid bills, and other obligations.	$215.60M	$215.80M	$18.81M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$233.06M	$222.94M	$347.51M

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$22.80M	$42.00M	-$59.36M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.70M	$3.99M	$9.73M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$27.50M	$38.01M	-$69.09M